Biondvax Pharma Wt (BVXVW) 0.59 $BVXVW BiondVax
Post# of 273331
Posted On: 09/24/2016 3:02:34 PM
Biondvax Pharma Wt (BVXVW) 0.59 $BVXVW
BiondVax Pharmaceuticals Ltd. Announces Closing of U.S. Initial Public Offering
GlobeNewswire - Fri May 15, 11:13AM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) (Nasdaq:BVXVW), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of its previously announced U.S. initial public offering of 1,910,000 American Depositary Shares (ADSs), each ADS representing 40 of its ordinary shares, and warrants to purchase up to an aggregate of 1,910,000 ADSs at an offering price of $5.00 per ADS and $0.01 per warrant. In addition, the underwriter has partially exercised their option to purchase an additional 128,000 warrants to purchase 128,000 ADSs. The warrants have a per ADS exercise price of $6.25, are exercisable immediately and will expire on May 15, 2020. Gross proceeds to BiondVax from this offering are approximately $9.57 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by BiondVax.
BVXVW: 0.59 (-0.01), BVXV: 3.68 (+0.08)
BiondVax Pharmaceuticals Ltd. Announces Pricing of U.S. Initial Public Offering of 1,910,000 ADSs and Warrants to Purchase 1,910,000 ADSs
GlobeNewswire - Mon May 11, 7:12PM CDT
BiondVax Pharmaceuticals Ltd (Nasdaq:BVXV) (Nasdaq:BVXVW), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the pricing of its initial public offering in the United States of 1,910,000 American Depositary Shares (ADSs), each ADS representing 40 of its ordinary shares, and warrants to purchase 1,910,000 ADSs at an offering price of $5.00 per ADS and $0.01 per warrant. The warrants will have a per ADS exercise price of $6.25, are exercisable immediately and will expire on May 15, 2020.
BVXVW: 0.59 (-0.01), BVXV: 3.68 (+0.08)
BiondVax Pharmaceuticals Ltd. Announces Closing of U.S. Initial Public Offering
GlobeNewswire - Fri May 15, 11:13AM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) (Nasdaq:BVXVW), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of its previously announced U.S. initial public offering of 1,910,000 American Depositary Shares (ADSs), each ADS representing 40 of its ordinary shares, and warrants to purchase up to an aggregate of 1,910,000 ADSs at an offering price of $5.00 per ADS and $0.01 per warrant. In addition, the underwriter has partially exercised their option to purchase an additional 128,000 warrants to purchase 128,000 ADSs. The warrants have a per ADS exercise price of $6.25, are exercisable immediately and will expire on May 15, 2020. Gross proceeds to BiondVax from this offering are approximately $9.57 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by BiondVax.
BVXVW: 0.59 (-0.01), BVXV: 3.68 (+0.08)
BiondVax Pharmaceuticals Ltd. Announces Pricing of U.S. Initial Public Offering of 1,910,000 ADSs and Warrants to Purchase 1,910,000 ADSs
GlobeNewswire - Mon May 11, 7:12PM CDT
BiondVax Pharmaceuticals Ltd (Nasdaq:BVXV) (Nasdaq:BVXVW), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the pricing of its initial public offering in the United States of 1,910,000 American Depositary Shares (ADSs), each ADS representing 40 of its ordinary shares, and warrants to purchase 1,910,000 ADSs at an offering price of $5.00 per ADS and $0.01 per warrant. The warrants will have a per ADS exercise price of $6.25, are exercisable immediately and will expire on May 15, 2020.
BVXVW: 0.59 (-0.01), BVXV: 3.68 (+0.08)
(0)
(0)